<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02342704</url>
  </required_header>
  <id_info>
    <org_study_id>101MS408</org_study_id>
    <secondary_id>2013-004622-29</secondary_id>
    <nct_id>NCT02342704</nct_id>
  </id_info>
  <brief_title>Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants</brief_title>
  <acronym>REVEAL</acronym>
  <official_title>A Multicenter, Randomized, Open-Label Study to Assess the Impact of Natalizumab Versus Fingolimod on Central Nervous System Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the effect of natalizumab compared to
      fingolimod on the evolution of new on-treatment T1-gadolinium-enhancing (Gd+) lesions to
      persistent black holes (PBH) over 52 weeks. The secondary objectives of this study in this
      study population are to assess the effect of natalizumab compared to fingolimod on: magnetic
      resonance imaging (MRI) measures of central nervous system (CNS) tissue destruction as
      measured by the number of new T1-Gd+ lesions; various other MRI measures of disease activity;
      No Evidence of Disease Activity (NEDA); Relapse on treatment over 52 weeks; The change in
      information processing speed as measured by the Symbol Digit Modalities Test (SDMT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study also includes a Diffusion Tensor Imaging (DTI) sub-study that includes healthy
      volunteers. Healthy volunteers will not receive any study medication.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business Decision
  </why_stopped>
  <start_date type="Actual">November 30, 2014</start_date>
  <completion_date type="Actual">May 18, 2016</completion_date>
  <primary_completion_date type="Actual">May 18, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Number of ≥ 6-Month Confirmed T1-Hypointense Lesions Arising From New On-Treatment T1-Gadolinium-Enhancing (Gd+) Lesions</measure>
    <time_frame>Up to Week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative Number of New T1-Gd+ Lesions</measure>
    <time_frame>Baseline, Week 4, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total T1-Hypointense and Total T2-Hyperintense Lesion Volumes at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>As assessed by magnetic resonance imaging (MRI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total T1-Hypointense and Total T2-Hyperintense Lesion Volumes at Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>As assessed by MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Number of New or Enlarging T2 Lesions</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With No Evidence of Disease Activity (NEDA)</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>NEDA was defined as all of the following: no relapses; no 12-week confirmed disability progression based on Expanded Disability Status Scale (EDSS; defined as an increase of 1.0 or more on the EDSS from baseline of 1.0 or more, or an increase of 1.5 or more from a baseline score of 0) that was sustained for 12 weeks; no new T1-Gd+ lesions on brain MRI. No new or enlarging T2-hyperintense lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Relapse</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>A clinical relapse was defined as new or recurrent neurological symptoms, not associated with fever, lasting for at least 24 hours, and followed by a period of 30 days of stability or improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Risk of Relapse</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>A clinical relapse was defined as new or recurrent neurological symptoms, not associated with fever, lasting for at least 24 hours, and followed by a period of 30 days of stability or improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Complete Recovery From First Relapse</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>12-week confirmed complete EDSS recovery from first on-treatment relapse is defined as an EDSS score that is equal to or lower than the last pre-relapse EDSS score and sustained for at least 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Symbol Digit Modalities Test (SDMT) at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The SDMT measures the time to pair abstract symbols with specific numbers. The test requires elements of attention, visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items from 0-110 in 90 seconds. The total score provides a measure of the speed and accuracy of symbol-digit substitution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SDMT at Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>The SDMT measures the time to pair abstract symbols with specific numbers. The test requires elements of attention, visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items from 0-110 in 90 seconds. The total score provides a measure of the speed and accuracy of symbol-digit substitution.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Relapsing-Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>natalizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label natalizumab 300 mg IV every 4 weeks (Q4W)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fingolimod</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Open-label fingolimod 0.5 mg once daily orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>natalizumab</intervention_name>
    <description>Administered as specified in the treatment arm</description>
    <arm_group_label>natalizumab</arm_group_label>
    <other_name>BG00002</other_name>
    <other_name>Tysabri</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fingolimod</intervention_name>
    <description>Administered as specified in the treatment arm</description>
    <arm_group_label>fingolimod</arm_group_label>
    <other_name>FTY720</other_name>
    <other_name>Gilenya</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria for MS Patients:

          -  Must have a documented diagnosis of relapsing MS (McDonald 2010 Criteria) at study
             screening with EDSS score from 0.0 to 5.5.

          -  If the subject is on Betaseron, Rebif, Avonex, Copaxone, Extavia, Tecfidera, and
             Aubagio (BRACE-TA) at study screening:

          -  He/she must have been on therapy for at least 6 months (unless experiencing highly
             active disease), have at least 9 T2-hyperintense lesions on a brain MRI scan, and have
             experienced ≥1 relapse within the last 6 months prior to study screening with ≥1 new
             T1-Gd+ lesion on a brain MRI scan performed ≤6 months prior to study screening or ≥2
             new T2 lesions on a brain MRI scan performed ≤6 months prior to study screening, with
             comparison made to a T2 MRI scan performed up to 18 months before study screening

          -  If the subject has highly active disease, regardless of whether they are
             disease-modifying therapy (DMT)-naïve or had previous exposure to Betaseron, Rebif,
             Avonex, Copaxone, Extavia, Tecfidera, and Aubagio (BRACE-TA), they must have had ≥2
             disabling relapses in the 12 months prior to study screening and either ≥1 new T1-Gd+
             lesion on a brain MRI scan performed ≤6 months prior to study screening or ≥2 new T2
             lesions on a brain MRI scan performed ≤6 months prior to study screening, with
             comparison made to a T2 MRI scan performed up to 18 months before study screening

        Key Exclusion Criteria for MS Patients:

          -  Diagnosis of Primary Progressive Multiple Sclerosis and/or Secondary Progressive
             Multiple Sclerosis.

          -  History or positive test result at study screening for human immunodeficiency virus
             (HIV), hepatitis C virus (HCV) antibody or current hepatitis B infection (defined as
             positive for hepatitis B surface antigen [HBsAg] and/or hepatitis B core antibody
             [HBcAb]).

          -  Prior treatment with natalizumab or fingolimod.

          -  History of or known active malignant disease, including solid tumors and hematologic
             malignancies (subjects with cutaneous basal and squamous cell carcinoma that has been
             completely excised and considered cured prior to study screening remain eligible).

          -  History of opportunistic infections or any clinically significant major disease, as
             determined by the Investigator.

          -  A clinically significant infectious illness (e.g., pneumonia, septicemia) within the 1
             month prior to study screening.

          -  History of drug or alcohol abuse (as defined by the Investigator) within 1 year prior
             to study screening.

          -  Prior history of immunosuppressant use (e.g., mitoxantrone, azathioprine,
             methotrexate, cyclophosphamide, mycophenolate, cladribine, rituximab), or exposure to
             intravenous immunoglobulin (IGIV), monoclonal antibodies, cytokines, growth factors,
             soluble receptors, other recombinant products, or fusion proteins in the last 12
             months prior to study screening.

          -  History of myocardial infarction, unstable angina, stroke, transient ischemic attack,
             decompensated heart failure in last 6 months.

          -  Treatment with Class Ia (e.g., procainamide, quinidine, ajmaline, disopyramide) or
             Class III (amiodarone, bretylium, dofelitide, sotalol, ibulitide, azilimide)
             anti-arrhythmic drugs.

          -  Concurrent therapy with drugs that slow heart rate (e.g., beta-blockers, heart-rate
             lowering calcium channel blockers such as diltiazem or verapamil, or digoxin).

          -  Hypertension not controlled with prescribed medications.

          -  History of severe respiratory disease, pulmonary fibrosis or class III or IV chronic
             obstructive pulmonary disease.

          -  The use of live or live attenuated vaccination within 8 weeks of study screening.

        Key Inclusion Criteria for Healthy Volunteers:

          -  Subjects who are generally healthy as demonstrated by physical examination and by
             medical history, with no history or evidence of major illnesses, diseases, or
             disorders.

          -  Subjects of childbearing potential must practice effective contraception and be
             willing and able to continue contraception for duration of the study.

          -  No history of drug or alcohol abuse (as defined by the Investigator) within 1 year
             prior to study screening.

        Key Exclusion Criteria for Healthy Volunteers:

          -  Claustrophobia sufficient to interfere with generating reliable MRI scans.

          -  History of other major illness including neurological disorders as determined by the
             Investigator.

          -  Presence of a metal device affected by MRI (e.g., any type of electronic, mechanical
             or magnetic implant, cardiac pacemaker, aneurysm clips, implanted cardiac
             defibrillator) or potential ferromagnetic foreign body (metal slivers, metal shavings,
             other metal objects), which would be a contraindication for MRI.

          -  Women who are currently pregnant or breastfeeding, or who have a positive pregnancy
             test result at screening.

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30327</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37922</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Lambton Heights</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jihlava</city>
        <zip>58633</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrava - Poruba</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pardubice</city>
        <zip>532 03</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Teplice</city>
        <zip>415 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nimes</city>
        <state>Gard</state>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Libourne Cedex</city>
        <state>Gironde</state>
        <zip>33505</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toulouse cedex 9</city>
        <state>Haute Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Freiburg</city>
        <state>Baden Wuerttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Erbach</city>
        <state>Hessen</state>
        <zip>64711</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gianicolense</city>
        <state>Roma</state>
        <zip>87-00151</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malaga</city>
        <state>Málaga</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <state>Tenerife</state>
        <zip>38010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <zip>E 41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Göteborg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>SE5 9NU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glasgow</city>
        <state>Strathclyde</state>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Denmark</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2015</study_first_submitted>
  <study_first_submitted_qc>January 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2015</study_first_posted>
  <results_first_submitted>May 17, 2017</results_first_submitted>
  <results_first_submitted_qc>May 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 9, 2017</results_first_posted>
  <last_update_submitted>May 17, 2017</last_update_submitted>
  <last_update_submitted_qc>May 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Natalizumab</mesh_term>
    <mesh_term>Fingolimod Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 128 participants were screened, 111 participants were enrolled in the study. Three participants were not randomized and did not receive any dose of study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Natalizumab</title>
          <description>Open-label natalizumab 300 mg IV every 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Fingolimod</title>
          <description>Open-label fingolimod 0.5 mg once daily orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54">Safety Population: randomized participants who received at least 1 dose of study treatment.</participants>
                <participants group_id="P2" count="54">Safety Population: randomized participants who received at least 1 dose of study treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Termination</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Natalizumab</title>
          <description>Open-label natalizumab 300 mg IV every 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Fingolimod</title>
          <description>Open-label fingolimod 0.5 mg once daily orally</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
            <count group_id="B2" value="54"/>
            <count group_id="B3" value="108"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.19" spread="8.811"/>
                    <measurement group_id="B2" value="34.87" spread="8.731"/>
                    <measurement group_id="B3" value="36.53" spread="8.887"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Number of ≥ 6-Month Confirmed T1-Hypointense Lesions Arising From New On-Treatment T1-Gadolinium-Enhancing (Gd+) Lesions</title>
        <time_frame>Up to Week 52</time_frame>
        <population>The limited number of participants enrolled and the early termination of the study resulted in efficacy data not collected, and efficacy outcomes not analyzed, as per the pre-specified plan of analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Natalizumab</title>
            <description>Open-label natalizumab 300 mg IV every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fingolimod</title>
            <description>Open-label fingolimod 0.5 mg once daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Number of ≥ 6-Month Confirmed T1-Hypointense Lesions Arising From New On-Treatment T1-Gadolinium-Enhancing (Gd+) Lesions</title>
          <population>The limited number of participants enrolled and the early termination of the study resulted in efficacy data not collected, and efficacy outcomes not analyzed, as per the pre-specified plan of analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Number of New T1-Gd+ Lesions</title>
        <time_frame>Baseline, Week 4, Week 12, Week 24</time_frame>
        <population>Intent-to-treat population: all randomized participants who received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Natalizumab</title>
            <description>Open-label natalizumab 300 mg IV every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fingolimod</title>
            <description>Open-label fingolimod 0.5 mg once daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Number of New T1-Gd+ Lesions</title>
          <population>Intent-to-treat population: all randomized participants who received at least 1 dose of study treatment.</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>From Baseline to Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" spread="1.512"/>
                    <measurement group_id="O2" value="1.69" spread="4.122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>From Baseline to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="1.695"/>
                    <measurement group_id="O2" value="2.27" spread="4.499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>From Baseline to Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" spread="1.69"/>
                    <measurement group_id="O2" value="2.6" spread="4.745"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1260</p_value>
            <method>Wilcoxon rank-sum test</method>
            <method_desc>p-value is based on Wilcoxon rank-sum test between the 2 treatment groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3525</p_value>
            <method>negative binomial regression</method>
            <method_desc>p-value is based on negative binomial regression model, adjusted for baseline GD lesion count</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0127</p_value>
            <method>Wilcoxon rank-sum test</method>
            <method_desc>p-value is based on Wilcoxon rank-sum test between the 2 treatment groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0299</p_value>
            <method>negative binomial regression</method>
            <method_desc>p-value is based on negative binomial regression model, adjusted for baseline GD lesion count</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0123</p_value>
            <method>Wilcoxon rank-sum test</method>
            <method_desc>p-value is based on Wilcoxon rank-sum test between the 2 treatment groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0076</p_value>
            <method>negative binomial regression</method>
            <method_desc>p-value is based on negative binomial regression model, adjusted for baseline GD lesion count</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total T1-Hypointense and Total T2-Hyperintense Lesion Volumes at Week 24</title>
        <description>As assessed by magnetic resonance imaging (MRI).</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Intent-to-treat population: all randomized participants who received at least 1 dose of study treatment and had an assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Natalizumab</title>
            <description>Open-label natalizumab 300 mg IV every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fingolimod</title>
            <description>Open-label fingolimod 0.5 mg once daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total T1-Hypointense and Total T2-Hyperintense Lesion Volumes at Week 24</title>
          <description>As assessed by magnetic resonance imaging (MRI).</description>
          <population>Intent-to-treat population: all randomized participants who received at least 1 dose of study treatment and had an assessment.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T1 Lesion Volume Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="31.235"/>
                    <measurement group_id="O2" value="1.81" spread="19.703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2 Lesion Volume Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="4.399"/>
                    <measurement group_id="O2" value="3.32" spread="5.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>T1 Lesion Volume Change</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5318</p_value>
            <method>Wilcoxon rank-sum test</method>
            <method_desc>p-value is based on Wilcoxon rank-sum test between the 2 treatment groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>T2 Lesion Volume Change</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0528</p_value>
            <method>Wilcoxon rank-sum test</method>
            <method_desc>p-value is based on Wilcoxon rank-sum test between the 2 treatment groups</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total T1-Hypointense and Total T2-Hyperintense Lesion Volumes at Week 52</title>
        <description>As assessed by MRI.</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>Intent-to-treat population: all randomized participants who received at least 1 dose of study treatment and had an assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Natalizumab</title>
            <description>Open-label natalizumab 300 mg IV every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fingolimod</title>
            <description>Open-label fingolimod 0.5 mg once daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total T1-Hypointense and Total T2-Hyperintense Lesion Volumes at Week 52</title>
          <description>As assessed by MRI.</description>
          <population>Intent-to-treat population: all randomized participants who received at least 1 dose of study treatment and had an assessment.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T1 Lesion Volume Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-15.31">only 1 participant had an assessment</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2 Lesion Volume Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="5.6">only 1 participant had an assessment</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Number of New or Enlarging T2 Lesions</title>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Intent-to-treat population: all randomized participants who received at least 1 dose of study treatment and had an assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Natalizumab</title>
            <description>Open-label natalizumab 300 mg IV every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fingolimod</title>
            <description>Open-label fingolimod 0.5 mg once daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Number of New or Enlarging T2 Lesions</title>
          <population>Intent-to-treat population: all randomized participants who received at least 1 dose of study treatment and had an assessment.</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="2.469"/>
                    <measurement group_id="O2" value="1.94" spread="2.205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2632</p_value>
            <method>Wilcoxon rank-sum test</method>
            <method_desc>p-value is based on Wilcoxon rank-sum test between the 2 treatment groups</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With No Evidence of Disease Activity (NEDA)</title>
        <description>NEDA was defined as all of the following: no relapses; no 12-week confirmed disability progression based on Expanded Disability Status Scale (EDSS; defined as an increase of 1.0 or more on the EDSS from baseline of 1.0 or more, or an increase of 1.5 or more from a baseline score of 0) that was sustained for 12 weeks; no new T1-Gd+ lesions on brain MRI. No new or enlarging T2-hyperintense lesions.</description>
        <time_frame>Up to Week 52</time_frame>
        <population>The limited number of participants enrolled and the early termination of the study resulted in efficacy data not collected, and efficacy outcomes not analyzed, as per the pre-specified plan of analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Natalizumab</title>
            <description>Open-label natalizumab 300 mg IV every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fingolimod</title>
            <description>Open-label fingolimod 0.5 mg once daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With No Evidence of Disease Activity (NEDA)</title>
          <description>NEDA was defined as all of the following: no relapses; no 12-week confirmed disability progression based on Expanded Disability Status Scale (EDSS; defined as an increase of 1.0 or more on the EDSS from baseline of 1.0 or more, or an increase of 1.5 or more from a baseline score of 0) that was sustained for 12 weeks; no new T1-Gd+ lesions on brain MRI. No new or enlarging T2-hyperintense lesions.</description>
          <population>The limited number of participants enrolled and the early termination of the study resulted in efficacy data not collected, and efficacy outcomes not analyzed, as per the pre-specified plan of analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Relapse</title>
        <description>A clinical relapse was defined as new or recurrent neurological symptoms, not associated with fever, lasting for at least 24 hours, and followed by a period of 30 days of stability or improvement.</description>
        <time_frame>Up to Week 52</time_frame>
        <population>The limited number of participants enrolled and the early termination of the study resulted in efficacy data not collected, and efficacy outcomes not analyzed, as per the pre-specified plan of analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Natalizumab</title>
            <description>Open-label natalizumab 300 mg IV every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fingolimod</title>
            <description>Open-label fingolimod 0.5 mg once daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Relapse</title>
          <description>A clinical relapse was defined as new or recurrent neurological symptoms, not associated with fever, lasting for at least 24 hours, and followed by a period of 30 days of stability or improvement.</description>
          <population>The limited number of participants enrolled and the early termination of the study resulted in efficacy data not collected, and efficacy outcomes not analyzed, as per the pre-specified plan of analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Risk of Relapse</title>
        <description>A clinical relapse was defined as new or recurrent neurological symptoms, not associated with fever, lasting for at least 24 hours, and followed by a period of 30 days of stability or improvement.</description>
        <time_frame>Up to Week 52</time_frame>
        <population>The limited number of participants enrolled and the early termination of the study resulted in efficacy data not collected, and efficacy outcomes not analyzed, as per the pre-specified plan of analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Natalizumab</title>
            <description>Open-label natalizumab 300 mg IV every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fingolimod</title>
            <description>Open-label fingolimod 0.5 mg once daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Risk of Relapse</title>
          <description>A clinical relapse was defined as new or recurrent neurological symptoms, not associated with fever, lasting for at least 24 hours, and followed by a period of 30 days of stability or improvement.</description>
          <population>The limited number of participants enrolled and the early termination of the study resulted in efficacy data not collected, and efficacy outcomes not analyzed, as per the pre-specified plan of analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Complete Recovery From First Relapse</title>
        <description>12-week confirmed complete EDSS recovery from first on-treatment relapse is defined as an EDSS score that is equal to or lower than the last pre-relapse EDSS score and sustained for at least 12 weeks.</description>
        <time_frame>Up to Week 52</time_frame>
        <population>The limited number of participants enrolled and the early termination of the study resulted in efficacy data not collected, and efficacy outcomes not analyzed, as per the pre-specified plan of analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Natalizumab</title>
            <description>Open-label natalizumab 300 mg IV every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fingolimod</title>
            <description>Open-label fingolimod 0.5 mg once daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Complete Recovery From First Relapse</title>
          <description>12-week confirmed complete EDSS recovery from first on-treatment relapse is defined as an EDSS score that is equal to or lower than the last pre-relapse EDSS score and sustained for at least 12 weeks.</description>
          <population>The limited number of participants enrolled and the early termination of the study resulted in efficacy data not collected, and efficacy outcomes not analyzed, as per the pre-specified plan of analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Symbol Digit Modalities Test (SDMT) at Week 24</title>
        <description>The SDMT measures the time to pair abstract symbols with specific numbers. The test requires elements of attention, visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items from 0-110 in 90 seconds. The total score provides a measure of the speed and accuracy of symbol-digit substitution.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Intent-to-treat population: all randomized participants who received at least 1 dose of study treatment and had both baseline and post-baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Natalizumab</title>
            <description>Open-label natalizumab 300 mg IV every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fingolimod</title>
            <description>Open-label fingolimod 0.5 mg once daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Symbol Digit Modalities Test (SDMT) at Week 24</title>
          <description>The SDMT measures the time to pair abstract symbols with specific numbers. The test requires elements of attention, visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items from 0-110 in 90 seconds. The total score provides a measure of the speed and accuracy of symbol-digit substitution.</description>
          <population>Intent-to-treat population: all randomized participants who received at least 1 dose of study treatment and had both baseline and post-baseline values.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.79" spread="8.684"/>
                    <measurement group_id="O2" value="3.24" spread="4.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SDMT at Week 52</title>
        <description>The SDMT measures the time to pair abstract symbols with specific numbers. The test requires elements of attention, visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items from 0-110 in 90 seconds. The total score provides a measure of the speed and accuracy of symbol-digit substitution.</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>Intent-to-treat population: all randomized participants who received at least 1 dose of study treatment and had both baseline and post-baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Natalizumab</title>
            <description>Open-label natalizumab 300 mg IV every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fingolimod</title>
            <description>Open-label fingolimod 0.5 mg once daily orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SDMT at Week 52</title>
          <description>The SDMT measures the time to pair abstract symbols with specific numbers. The test requires elements of attention, visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items from 0-110 in 90 seconds. The total score provides a measure of the speed and accuracy of symbol-digit substitution.</description>
          <population>Intent-to-treat population: all randomized participants who received at least 1 dose of study treatment and had both baseline and post-baseline values.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2.11" spread="8.492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 64 weeks.</time_frame>
      <desc>Treatment-emergent adverse events are presented.</desc>
      <group_list>
        <group group_id="E1">
          <title>Natalizumab</title>
          <description>Open-label natalizumab 300 mg IV every 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Fingolimod</title>
          <description>Open-label fingolimod 0.5 mg once daily orally</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine with aura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Biogen Study Medical Director</name_or_title>
      <organization>Biogen</organization>
      <email>clinicaltrials@biogen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

